Title |
Evaluation of Low-density Lipoprotein Cholesterol Target Attainment Rates According to the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society Dyslipidemia Guidelines for Secondary Prevention in Patients with Acute Myocardial Infarction.
|
---|---|
Published in |
Revista de investigación clínica, November 2021
|
DOI | 10.24875/ric.21000152 |
Pubmed ID | |
Authors |
Barış Şimşek, Duygu İnan, Tufan Çınar, Ahmet Cagdas-Yumurtaş, Veysel Ozan-Tanık, Gonul Zeren, İlhan İlker-Avcı, Can Yücel-Karabay, Barış Güngör, Lale Tokgozoğlu |
Abstract |
High-intensity statin (HIS) therapy is widely recommended for secondary prevention after an acute myocardial infarction (AMI). The 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) dyslipidemia guidelines have lowered the target low-density lipoprotein cholesterol (LDL-C) level, which necessitates a more frequent use of nonstatin therapies. The objectives of the study were to investigate the rate of LDL-C target attainment for secondary prevention in AMI patients. This retrospective investigation included 1360 patients diagnosed with AMI in a tertiary heart center. Lipid parameters were collected within 24 h of admission and within 1 year after discharge. The medications used were retrieved from medical records, and the lowest LDL-C levels after statin treatment were used to assess the effectiveness of the therapy. LDL-C target attainment was defined according to the 2016 ESC/EAS dyslipidemia guidelines as an LDL-C level of < 70 mg/dL and a ≥ 50% reduction from baseline. In addition, the rate of LDL-C target attainment according to the 2019 fromESC/EAS guidelines was defined as an LDL-C level of < 55 mg/dL and a ≥ 50% reduction baseline. In total, 502 (36.9%) and 247 (18.2%) patients reached the LDL-C targets according to the 2016 and 2019 ESC/EAS guidelines, respectively. The admission LDL-C levels were significantly lower and HIS treatment was used more frequently in patients who subsequently attained the LDL-C goal. Remarkably, 461 (34%) patients failed to reach the LDL-C goals despite HIS treatment. Only 27 (1.9%) patients were prescribed ezetimibe. The rate of LDL-C goal attainment in AMI patients was low, which indicates the need for combination statin and non-statin lipid-lowering therapies. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Mexico | 2 | 18% |
Spain | 1 | 9% |
Ecuador | 1 | 9% |
Argentina | 1 | 9% |
Unknown | 6 | 55% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 10 | 91% |
Scientists | 1 | 9% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 8 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Unspecified | 2 | 25% |
Student > Bachelor | 1 | 13% |
Student > Doctoral Student | 1 | 13% |
Unknown | 4 | 50% |
Readers by discipline | Count | As % |
---|---|---|
Unspecified | 2 | 25% |
Medicine and Dentistry | 2 | 25% |
Unknown | 4 | 50% |